RGT — Argent BioPharma Income Statement
0.000.00%
Last trade - 00:00
- AU$13.32m
- AU$6.62m
- AU$3.39m
R2019 June 30th | 2020 June 30th | R2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.656 | 2.08 | 3 | 4.73 | 3.39 |
Cost of Revenue | |||||
Gross Profit | 0.3 | 0.175 | 1.1 | 1.64 | 1.29 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 11.9 | 20.7 | 18.5 | 25.3 | 24.5 |
Operating Profit | -11.2 | -18.6 | -15.5 | -20.6 | -21.1 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11 | -18.8 | -15.9 | -20.8 | -21.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11.1 | -18.8 | -15.9 | -20.8 | -21.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -8.58 | -19.4 | -15.9 | -20.3 | -20.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.58 | -19.4 | -15.9 | -20.3 | -20.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -8.02 | -9.87 | -8.33 | -5.99 | -6.07 |